Table 3.
Discontinuation and switching rates for responders and non-responders [8 and Interviews with clinical experts]
| Responders | Non-responders | |||
|---|---|---|---|---|
| 2 year | 4-weekly rate | 2 year | 4-weekly rate | |
| Discontinuation rates | ||||
| FDC tablet solifenacin 6 mg + TOCAS | 43.0% | 0.023 | 53.0% | 0.031 |
| Tolterodine + tamsulosin | 59.8% | 0.037 | 69.8% | 0.049 |
| Switching rates | ||||
| FDC tablet solifenacin 6 mg + TOCAS | 15.3% | 0.007 | 15.3% | 0.007 |
| Tolterodine + tamsulosin | 23.3% | 0.011 | 23.3% | 0.011 |
FDC, fixed-dose combination; TOCAS, oral controlled absorption system (OCAS™) formulation of tamsulosin.